Amgen AMGN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $36.75B+10.0% | $33.42B+18.6% | $28.19B+7.1% | $26.32B+1.3% | ||
| $12.04B-6.4% | $12.86B+52.1% | $8.45B+31.9% | $6.41B-0.7% | ||
| $24.71B+20.2% | $20.57B+4.2% | $19.74B-0.9% | $19.92B+2.0% | ||
| 67.2%+5.7pp | 61.5%-8.5pp | 70%-5.6pp | 75.7%+0.5pp | ||
| $7.27B+21.9% | $5.96B+24.7% | $4.78B+7.9% | $4.43B-8.0% | ||
| $7.05B-0.6% | $7.1B+14.8% | $6.18B+14.1% | $5.41B+0.9% | ||
| $27.67B+5.8% | $26.17B+28.9% | $20.29B+21.1% | $16.76B-8.6% | ||
| $9.08B+25.1% | $7.26B-8.1% | $7.9B-17.4% | $9.57B+25.2% | ||
| 24.7%+3.0pp | 21.7%-6.3pp | 28%-8.3pp | 36.3%+6.9pp | ||
| $2.76B-12.7% | $3.16B+9.7% | $2.88B+104% | $1.41B+17.5% | ||
| —— | —— | $2.83B+448% | -$814M-414% | ||
| $8.98B+94.7% | $4.61B-41.3% | $7.86B+6.9% | $7.35B+9.6% | ||
| $1.27B+144% | $519M-54.4% | $1.14B+43.3% | $794M-1.7% | ||
| $7.71B+88.5% | $4.09B-39.1% | $6.72B+2.5% | $6.55B+11.2% | ||
| 21%+8.7pp | 12.2%-11.6pp | 23.8%-1.1pp | 24.9%+2.2pp | ||
| $14.24+88.6% | $7.55-39.6% | $12.50+3.2% | $12.11+17.6% | ||
| $14.25B+10.9% | $12.85B+7.4% | $11.97B-7.8% | $12.98B+17.6% | ||
| 38.8%+0.3pp | 38.4%-4.0pp | 42.5%-6.9pp | 49.3%+6.8pp | ||
| $9.08B+25.1% | $7.26B-8.1% | $7.9B-17.4% | $9.57B+25.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amgen's revenue?
- Amgen (AMGN) generated $37.2B in revenue over the trailing twelve months, up 9.1% year over year.
- Is Amgen profitable?
- Amgen reported $7.8B in net income over the trailing twelve months, a 21.0% net margin.
- What are Amgen's profit margins?
- Gross margin is 68.3% and operating margin is 28.4%, with a 21.0% net margin.
- What is Amgen's earnings per share?
- Amgen's diluted EPS over the trailing twelve months is $14.38.
- Where does Amgen's income statement data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
